Combination treatment in hypertension: the VeraTran Study.

In the past few years, the combination of two antihypertensive drugs has become a popular approach to hypertension treatment, because this procedure allows one to obtain satisfactory blood pressure control when monotherapy is partially ineffective and also to improve a patient's adherence to the therapeutic regimen, thereby enhancing the tolerance/effectiveness ratio of the treatment. This paper will briefly review the theoretical background and the requirements for an effective combination treatment. It will also discuss the results of the VeraTran Study, a multicenter study performed according to a double-blind parallel group design and aimed at assessing the antihypertensive efficacy of the fixed combination verapamil slow release (SR) and trandolapril, administered for 8 weeks, on clinic and 24-h ambulatory blood pressure. The results of the study demonstrate that the fixed combination of a calcium antagonist and an angiotensin converting enzyme (ACE) inhibitor allows one to obtain an effective and balanced blood pressure control throughout the 24 h.

RCT Entities:   Population Interventions Outcomes